Incidence and Clinical Characteristics of Pulmonary Hypertension Secondary to ARDS in the Highland

Incidence and Clinical Characteristics of Pulmonary Hypertension Secondary to ARDS

The study is conducted in the affiliated hospital of Qinghai University .Patients in the department of Critical Care Medicine and Emergency Intensive Care Unit will be eligible for inclusion if they meet the Berlin criteria.Two researchers assess pulmonary artery pressure and right heart function of patients who are enrolled.

Study Overview

• Status: Recruiting
• Conditions: ARDS
• Intervention / Treatment: Device: Doppler ultrasound

• Study Type: Observational
• Enrollment (Anticipated): 100

Contacts and Locations

• Study Contact: Name: Chun Pan, MD; Phone Number: 13814009925; Email: panchun1982@gmail.com
• Study Contact Backup: Name: Peng Zhu; Phone Number: 18625195060; Email: sqzhupeng@163.com

Study Locations

• China
  • Qinghai
    • Xining, Qinghai, China
      • Recruiting
      • Affiliated Hospital of Qinghai University
      • Contact: Chun Pan, MD; Phone Number: 13814009925; Email: panchun1982@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

The study is conducted in the affiliated hospital of Qinghai University .Patients in the department of Critical Care Medicine and Emergency Intensive Care Unit will be eligible for inclusion if they meet the Berlin criteria.Two researchers assess pulmonary artery pressure and right heart function of patients who are enrolled.

Description

Inclusion Criteria:

Inclusion Criteria:

18 to 80 years of age Meet the diagnostic criteria Receive invasive mechanical ventilation within 48 hours

-

Exclusion Criteria:

Patients with those disease will be excluded ： chronic obstructive pulmonary disease Pulmonary embolism Chronic heart failure Idiopathic pulmonary fibrosis Pulmonary hypertension Pregnant women will be excluded too.

-

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Pulmonary Hypertension Secondary to ARDS in the Highland		20/11/2021-20/12/2022
ICU mortality ICU mortality	Mortality during treatment in ICU	20/11/2021-20/12/2022
28-days mortality rate	Mortality at 28 days of hospitalization	20/11/2021-20/12/2022

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ventilator time	Ventilator time in ICU	20/11/2021-20/12/2022
Hospital length of stay	Total length of stay in hospital	20/11/2021-20/12/2022

Other Outcome Measures

Outcome Measure	Time Frame
Right cardiac functionof Pulmonary Hypertension Secondary to ARDS in the Highland	20/11/2021-20/12/2022

Collaborators and Investigators

• Sponsor: Southeast University, China
• Collaborators: Qinghai University
• Investigators: Principal Investigator: Chun Pan, MD, Qinghai University

Study record dates

Study Major Dates

• Study Start (Actual): November 25, 2021
• Primary Completion (Anticipated): March 1, 2022
• Study Completion (Anticipated): December 1, 2022

Study Registration Dates

• First Submitted: December 20, 2021
• First Submitted That Met QC Criteria: December 21, 2021
• First Posted (Actual): December 22, 2021

Study Record Updates

• Last Update Posted (Actual): December 22, 2021
• Last Update Submitted That Met QC Criteria: December 21, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Lung Diseases; Hypertension; Hypertension, Pulmonary
• Other Study ID Numbers: ARDS in the highland

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No